Company Overview

Owlet, Inc. is a U.S.-based medical technology and consumer health company focused on connected infant and child monitoring solutions. The company operates at the intersection of digital health, consumer electronics, and pediatric medical devices, developing products designed to track vital signs, sleep patterns, and overall wellness in infants and young children. Owlet’s offerings combine wearable sensors, mobile software, and cloud-based analytics to provide caregivers with health-related insights.

The company’s primary revenue drivers are its smart monitoring devices and related software-enabled services sold directly to consumers and, in regulated contexts, through healthcare channels. Owlet primarily serves parents, caregivers, and healthcare providers, positioning itself as a differentiated provider of clinically informed monitoring solutions for early childhood. Founded in 2013, Owlet initially gained traction with its smart sock infant monitor, evolved through rapid consumer adoption, faced regulatory scrutiny in the U.S., and later transitioned toward FDA-authorized medical-grade products. Owlet became a public company in 2021 through a merger with a special purpose acquisition company.

Business Operations

Owlet conducts its business primarily through Owlet Baby Care Inc., its main operating subsidiary, which designs, markets, and distributes connected monitoring products. The company generates revenue from hardware sales such as smart socks and camera systems, as well as associated mobile application functionality and data services. Operations span both consumer wellness products and regulated medical devices, depending on jurisdiction and product classification.

The company maintains domestic operations in the United States and international operations in markets including Europe and Asia-Pacific, supported by third-party manufacturing partners and logistics providers. Owlet controls proprietary sensor technology, software platforms, and mobile applications that integrate biometric data with real-time alerts. Partnerships include contract manufacturers and distribution relationships with major retailers and e-commerce platforms; no material joint ventures have been consistently disclosed in public filings.

Strategic Position & Investments

Owlet’s strategic direction centers on expanding its presence in regulated pediatric healthcare while maintaining its consumer wellness business. A key strategic initiative has been obtaining regulatory authorization for medical-grade infant monitoring products, including FDA clearance for prescription-based pulse oximetry solutions. This shift is intended to strengthen clinical credibility and enable reimbursement-based revenue opportunities.

The company has invested in product development focused on advanced biosensing, cloud connectivity, and software analytics rather than large-scale acquisitions. Public disclosures indicate that Owlet’s growth strategy relies more on internal innovation and regulatory milestones than on inorganic expansion. If information regarding specific minority investments or external portfolio holdings exists, it is not consistently detailed across available public sources; data inconclusive based on available public sources.

Geographic Footprint

Owlet is headquartered in the United States, with its principal executive offices located in Utah. The company sells products primarily in North America, which represents its largest market by revenue, supported by both direct-to-consumer sales and retail distribution channels.

Internationally, Owlet has an established presence in Europe, particularly the United Kingdom, where certain products have been marketed under medical device frameworks, as well as selective markets in Asia-Pacific and other regions. International operations are largely sales- and distribution-focused, with manufacturing concentrated through global supply chain partners rather than company-owned facilities.

Leadership & Governance

Owlet was co-founded by Kurt Workman, who has played a central role in shaping the company’s product vision and regulatory strategy. The leadership team emphasizes a mission-driven approach centered on improving infant health outcomes through accessible technology, with increased focus on compliance, clinical validation, and long-term sustainability following the company’s transition to public markets.

Key executives include:

• Kurt Workman – Chief Executive Officer
• Jordan Monroe – Chief Financial Officer
• Jonathan Harris – Chief Technology Officer
• Melanie Cook – Chief Operating Officer

The company is governed by a board of directors with experience in healthcare, technology, and public company oversight, reflecting Owlet’s dual positioning as both a consumer technology brand and a regulated medical device company.